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A number of protein toxins produced by bacteria and plants enter eukaryotic cells and inhibit pro-
tein synthesis enzymatically. These toxins include the plant toxin ricin and the bacterial toxin Shiga
toxin, which we will focus on in this article. Although a threat to human health, toxins are valuable
tools to discover and characterize cellular processes such as endocytosis and intracellular transport.
Bacterial infections associated with toxin production are a problem worldwide. Increased knowl-
edge about toxins is important to prevent and treat these diseases in an optimal way. Interestingly,
toxins can be used for diagnosis and treatment of cancer.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction toxins seem to be an increasing health problem also in modernA large number of bacterial toxins, such as Shiga toxin produced
by Shigella dysenteriae, Shiga-like toxins produced by Escherichia
coli, diphtheria toxin, Pseudomonas exotoxin A, and cholera toxin
consist of two moieties, one that binds to the cell surface and an-
other, enzymatically active part, that enters the cytosol and exerts
the action (for review, see [1–7]). With exception of cholera toxin,
all of the above-mentioned toxins inhibit protein synthesis. Simi-
larly, a number of plant toxins have two moieties, one that binds
to the cell surface and another that enters the cytosol, and like Shi-
ga and Shiga-like toxins, they inhibit protein synthesis by remov-
ing one single adenine from the 28S RNA of the 60S ribosomal
subunit [1,2]. This group of toxins comprises ricin, abrin, modeccin,
viscumin and volkensin, all found in different plants [2]. The sche-
matic and crystallographic structures of Shiga toxin and ricin are
shown in Fig. 1.
Bacterial toxins are still a problem in connection with infectious
diseases, and E. coli as well as other bacteria producing Shiga-likechemical Societies. Published by E
e; SNX, sorting nexin; ER,
rovascular endothelial cells;
FAs, poly-unsaturated fatty
mistry, Institute for Cancer
rsity Hospital, Montebello, N-
ig).societies [8–10]. These toxin-producing bacteria can be found asso-
ciated with various types of food, especially in meat, but also on
vegetables, in juices, water, etc. Ingestion of such toxin-producing
bacteria can cause diarrhea, hemolytic uremic syndrome (HUS) and
kidney failure, especially in children and in the elderly. Plant toxins
may cause intoxication by accident, but can also be used for crim-
inal purposes [11–13]. Although the toxins thus serve as a health
threat in their original form, promising studies are being per-
formed where their properties of binding to cells and penetrating
into the cytosol are exploited to bring epitopes into cells, and in
cancer diagnosis and therapy (for review, see [3,14–16]). One such
product is currently on the market, a diphtheria conjugate binding
via interleukin 2 to leukemia cells [17].
Studies of toxin transport have also, as described below, thrown
light on a number of cellular processes such as the different endo-
cytic mechanisms, and pathways of intracellular transport. More
information about the role of toxin domains in receptor binding
and membrane penetration will provide us with insight of how
we can exploit the toxins for our beneﬁt.2. Binding of plant and bacterial toxins to cell surface receptors
Plant and bacterial toxins bind to a large variety of cell surface
receptors, some toxins have strict requirements for binding and
intoxicate only certain cell types [18]. For instance, Shiga toxinlsevier B.V. All rights reserved.
Fig. 1. Structural and schematic models of Shiga toxin and ricin. (A) Stx (PDB protein data bank: 1DM0) consists of an A-moiety of 32 kDa, non-covalently attached to a B-
moiety composed of ﬁve 7.7 kDa B-chains. During intracellular toxin transport the A-moiety is cleaved by furin into the enzymatically active A1 fragment (27 kDa) and the
carboxyl terminal A2 fragment, which remain linked by a disulﬁde bond. (B) Ricin (PDB protein data bank: 2AAI) is composed of a binding moiety and an enzymatically active
A-moiety (each of 30 kDa) linked together by a disulﬁde bond. The structure images were prepared by PDB ProteinWorkshop 3.6 [109].
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which is expressed on only a few normal cell types, but on several
types of cancer cells, a feature that may be exploited for imaging of
cancer, and for therapeutic purposes (see below). Studies of the
interaction of Shiga toxin with Gb3 reveal that the pentamer of B
subunits in the toxin can bind up to 15 molecules of Gb3 [19].
However, these binding sites do not have equal afﬁnity for the car-
bohydrates of Gb3 and may play different roles for the attachment
of the toxin to the cell surface (a model is shown in [20]). Further-
more, toxin binding to Gb3 is unusually complex, as it is dependent
on the type of fatty acid in the Gb3 molecule to which the toxin
binds, and binding may occur more easily when there is a mixture
of different Gb3 species [6,21]. Moreover, binding can be depen-
dent on membrane phospholipids as well as the density of Gb3
and the cholesterol content of the membrane. It should be noted
that although both Shiga toxin/Shiga-like toxin 1 (only one amino
acid residue is different from Shiga toxin) and Shiga-like toxin 2
bind to Gb3, their dependency on Gb3 species (different N-amidat-
ed fatty acids) for binding differ. This may be important for their
different toxicities on cells in culture and their different effects in
humans. However, why Shiga-like toxin 2 seems more important
for disease is not understood.
Importantly, the experimental system used to study toxin–Gb3
interactions, such as toxin binding to Gb3 on thin layer chromato-
grams, binding to liposomes or to cells, may give different results
[6]. This is perhaps not so surprising since membrane constituents
and ﬂuidity are important for accessibility of the toxin to Gb3 and
the ability of the toxin to crosslink Gb3 in the membrane. Changes
in localization of Gb3, such as its localization to lipid rafts, would of
course only occur in membranes, and due to the difference in
membrane composition, one might also expect that results ob-
tained from studies of liposomes/lipid membranes would differ
from those obtained with cells. Also, in intact cells the toxin might
affect lipid rafts and the cellular cytoskeleton in a way not obtain-
able in artiﬁcial membranes [22–24]. Interestingly, even liposomes
and planar lipid membranes seem to differ [20,25]. It was recently
found that Shiga toxin-induced tubule formation in liposomes oc-
curred when the liposome contained either a semisynthetic C22:1
Gb3 or Gb3 puriﬁed from porcine kidney [25], but not when it con-
tained Gb3 with C22:0. However, in planar lipid membranes C22:0
behaved like porcine Gb3, whereas Gb3 with C22-1 did not [20].
The reason for this apparent discrepancy is not obvious.
In contrast to Shiga toxin, the plant toxin ricin binds to and intox-
icates most cell types (for review, see [2]). This plant toxin binds to
both glycoproteins and glycolipids with terminal galactose, and
there is no evidence for one type of productive receptor responsible
for retrograde transport and intoxication. Clearly not only glyco-sphingolipids can mediate toxicity, as cells are intoxicated with ri-
cin even when glycosphingolipid synthesis is inhibited [26–28].
Both in the case of bacterial and plant toxins one may, by
substituting the whole subunit responsible for binding with an-
other receptor-binding protein, change the binding speciﬁcity to
direct the toxins to certain cell types (for review, see [14,16,29–
33]). However, one might want to keep part of the binding subunit
if that improves the ability of the ‘‘new” toxin to penetrate into the
cytosol and intoxicate the cell. For instance, studies of diphtheria
toxin revealed that the B-chain, and even more speciﬁcally a por-
tion of the B-chain is important for penetration of this toxin
through the membrane [34]. Diphtheria toxin conjugates with al-
tered binding speciﬁcities therefore contain this portion of the ori-
ginal molecule [17].3. Endocytic uptake of protein toxins
The different protein toxins exploit a variety of the endocytic
mechanisms that exist in a cell, and they might even increase their
own uptake by signaling through kinases that affect molecules in-
volved in endocytosis, by crosslinking surface molecules and by
inducing changes in membrane curvature (for review, see
[3,7,35–37]). While at the cell surface or after endocytic uptake,
the toxins can become cleaved and activated by proteases such
as furin that cycles between the cell surface, endosomes and the
Golgi apparatus [38,39].
The view of today, that there are different endocytic pathways
[35,36] (Fig. 2) is partly due to early studies with toxins. During
many years, a quite general view was that endocytosis (with the
exception of macropinocytosis and phagocytosis) occurred through
clathrin-coated pits. However, experiments with ricin suggested
that this toxin could enter by clathrin-independent endocytosis
[40,41]. Both when clathrin-dependent uptake was blocked by re-
moval of clathrin with hypotonic shock and potassium-depletion
[40], or by ‘‘freezing” the coat at the cell surface by acidiﬁcation
of the cytosol [41], ricin was still endocytosed, demonstrating that
it was taken up independently of clathrin. However, one argument
was that when clathrin was no longer at the cell surface, perhaps
the rest of the machinery normally working together with clathrin
was sufﬁcient to mediate uptake, and perhaps acidiﬁcation caused
some abnormal cell behavior. Such arguments are of course valid
and could serve as a warning even today when siRNA allows us
to remove molecules of interest and one might get upregulation
of compensatory mechanisms. It was not until the ﬁnding that mu-
tant dynamin blocked clathrin-dependent endocytosis whereas
ﬂuid was still taken up [42] that it was generally accepted that
Fig. 2. Endocytic uptake and retrograde transport of Shiga toxin. The top panel shows an estimation of the amount of Shiga toxin entering by different pathways. See text for
details. The lower panel shows an overview of components reported to be involved in the intracellular transport pathway of Shiga toxin. Upon internalization the toxin is
sorted from the early endosomes (EE) into the retrograde pathway leading to the trans-Golgi network (TGN), and further to the endoplasmic reticulum (ER). From the ER the
enzymatically active A1 fragment is translocated to the cytosol where the 28S rRNA is targeted. The components highlighted in green are reported to be involved in the fusion
of incoming vesicles at the TGN. For reviews see [3,4,7,56].
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edged. It turns out that there are many challenges for studies of
endocytosis. It was found that when mutant dynamin blocked
clathrin-dependent endocytosis, ﬂuid was not only internalized,
but it was reported that ﬂuid uptake was actually upregulated by
other pathways [43]. Thus, the studies of today where we knock-
down certain molecules by siRNA over a time-frame of 2–5 days
or express mutant molecules at a level that leads to interaction
with mechanisms normally not affected, certainly may induce
upregulation of compensatory mechanisms that could give mis-
leading information about the normal state of the cell.
The mechanisms for the different clathrin-independent ways
of endocytosis are now being characterized in a number of lab-
oratories, but several details are still lacking, not only about the
molecules involved, but also about the relative importance of the
pathways when it comes to uptake of ﬂuid as well as uptake oflipid-binding ligands such as Shiga toxin and cholera toxin,
which can be taken in by clathrin-dependent as well as dynam-
in-independent pathways ([44–46] and see below). Also, in most
cases non-polarized cells are investigated, and we know that for
instance in polarized cells the clathrin-independent uptake of ri-
cin is under differential regulation at the apical and the basolat-
eral pole [1]. In MDCK cells caveolae are, for unknown reasons,
found only at the basolateral side, whereas clathrin-independent
endocytosis at the apical pole is under regulation by signaling
pathways that do not affect the basolateral uptake. Again, stud-
ies with ricin have been useful for elucidation of these mecha-
nisms, and uptake of ricin by apical clathrin-independent
endocytosis turns out to be regulated by protein kinase C, pro-
tein kinase A, cyclooxygenase, and calmodulin (for review, see
[1]). Furthermore, the uptake was found to be RhoA-dependent
[47].
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mechanisms. What about the Gb3-binding Shiga toxin? One might
think that since this toxin has only one type of receptor, only one
endocytic mechanism could be used. However, this is not the case,
and Shiga toxin can to a certain extent even mediate its own up-
take. It was recently shown that the toxin can induce membrane
tubules that pinch off in a dynamin-dependent manner [25], and
it was described that these tubules seem to originate from caveolar
structures [48]. However, this uptake mechanism may not contrib-
ute to any large extent to the total endocytic uptake [48] (Fig. 2).
On the other hand, Shiga toxin can enter both by clathrin-depen-
dent endocytosis (in spite of being bound to a glycolipid) and by
clathrin- and dynamin-independent endocytosis. In fact, Shiga
toxin induces an activation of Syk which in turn leads to
clathrin-phosphorylation [49,50], and Syk seems to be important
for endocytic uptake of the toxin. How, and if, clathrin-phosphory-
lation is important for Shiga toxin internalization is not yet clari-
ﬁed, and it is possible that phosphorylation of other molecules
involved in endocytosis might be essential. In that connection, it
is interesting to note that in Ramos cells Shiga toxin can activate
Src [50], a kinase that was recently published to be involved in
transferrin induced signaling leading to dynamin and cortactin
phosphorylation and increased clathrin-dependent uptake of
transferrin [51]. The clathrin- and dynamin-independent uptake
of Shiga toxin is responsible for 40–60% of toxin uptake in Hela
and BHK cells [45,52] (Fig. 2), but the mechanism(s) involved
remain to be characterized. The fraction of toxin entering by differ-
ent endocytic mechanisms is likely to be cell-type dependent as
the Gb3 level and fatty acid composition of cellular membranes
differ (Table 1). Probably the extent of Gb3 in rafts might deter-
mine signaling induced by the toxin as well as the ability of the
membrane to form invaginations of different types. Studies from
our own lab revealed that also the A-moiety of the toxin can affect
the internalization [52]. With increasing toxin concentrations there
is an A-chain dependent increase in toxin uptake by clathrin-
dependent endocytosis. Thus, studies of toxin internalization may
not give the same results as obtained when only the B-moieties
are used, and one should keep inmind that the A-chainmight affect
transport also at a later step on the way to the cytosol.
4. Endosome-to-Golgi transport of Shiga toxin and ricin
4.1. Proteins involved in sorting of toxins to the Golgi apparatus
Protein toxins behave quite differently also when it comes to
retrograde transport from endosomes to the Golgi apparatus. Not
only are several of the toxins, such as ricin and Shiga toxin quite
resistant to proteolytic enzymes, but they do in addition avoid
lysosomal enzymes by being transferred directly from early
endosomal compartments in the direction of the Golgi apparatus
[53,54]. Microscopical studies revealed that Shiga toxin wasTable 1
Percent of different fatty acid chain length of Gb3 species in various cell types.
Chain length HEp-2a HeLab HeLac XF-498d
24:1 50 8 30 7
Other 24 11 42 32 32
22 20 35 12 11
20 <3 – – 1
18 <3 4 4 23
16 16 6 19 20
a Raa et al. [27]; MS analyses.
b Smith et al. [79]; MS analyses.
c Falguieres et al. [80]; MS analyses; numbers given are our estimates of the data sho
d Arab and Lingwood [81]; fatty acid methyl esters quantiﬁed with chromatography f
e Muthing et al. [83]; the numbers given are our estimates based on the MS spectra prapidly transported to the Golgi apparatus from an early endo-
somal compartment [53], and ricin transport to the Golgi was
found to be Rab9 independent as cells with inducible synthesis
of dominant negative Rab9 showed no reduction in ricin transport
to the Golgi [54]. On the other hand, although there are similarities
between requirements for endosome-to-Golgi transport of these
two toxins, there are many differences, suggesting that there
may be more than one pathway between endosomes and the Golgi
apparatus [3,4,7,27,55,56]. It is important to note that the involve-
ment in Shiga toxin transport of somemolecules such as clathrin, is
more easily demonstrated at low toxin concentrations [45,57]. This
suggests that the machinery for efﬁcient Golgi transport may differ
from what one can observe at higher toxin concentrations, which
may allow the toxin to reach the Golgi apparatus via other, less
efﬁcient mechanisms. Some of the apparently contradictory results
reported in the literature may result from the use of different toxin
concentrations and of course from cell-to-cell differences.
A large number of endosomal proteins involved in Golgi trans-
port of toxins are now known [4,7,58–60]. Common to both Shiga
toxin and ricin is the importance of the PI3 kinase Vps34, involved
in production of PI3P which serves as a docking site for many endo-
somal proteins, including sorting nexins (SNXs) [61]. Toxin trans-
port have been found to be affected by SNX1, SNX2, SNX4 and
SNX8, but differences between the toxins are observed
[55,59,62–64]. The less characterized of these SNXs, SNX8, was re-
cently found to be endosome-associated, and curiously, knock-
down of SNX8 increases Golgi transport of Shiga toxin while ricin
transport is slightly reduced [55]. The possible association of
SNX8 with SNX1/SNX2-dependent transport needs to be investi-
gated. Also cytoskeletal elements are reported to be involved in
endosome-to-Golgi transport of toxins [23,24], and Rab-proteins
and v-/t-SNAREs have been characterized as parts of this machin-
ery [4,7,58]. Furthermore, it was recently reported that knockdown
of the proteins RME-8 or Hsc70 affects retrograde transport of both
Shiga toxin B subunit and the cation-independent mannose-6-
phosphate receptor [65]. However, in spite of all the details we
now have, it is still not clear how the many molecules involved
can coordinate endosomal functions including sorting to the Golgi.
For instance, are there parallel pathways, to which extent does
sorting go via the recycling compartment, and how does the
requirement for dynamin relate to the role of SNXs in Golgi
transport?
4.2. Involvement of kinases in regulation
of endosome-to-Golgi transport
Not only is there a large number of proteins and protein com-
plexes involved in sorting in the direction of the Golgi apparatus,
but the transport, at least that of Shiga toxin can be regulated by
kinases. When protein kinase C delta is downregulated by siRNA,
or blocked by addition of chemical inhibitors, transport of ShigaSF-539d SKOV3d SKVLBd HBMECe EA.hy 926e
9 15 1 30 30
23 12 1 26 40
9 8 2 6 10
1 2 1 – –
30 28 52 – –
26 28 42 38 20
wn for the plasma membranes in their Fig. 7.
ollowing hydrolysis of Gb3.
resented in their Fig. 5.
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the kinase p38a is deleted by siRNA, the Golgi transport of Shiga
toxin is reduced, and again, also inhibitors of this enzyme reduce
the transport [67,68]. Interestingly, none of these enzyme-activi-
ties seem to be required for endosome-to-Golgi transport of the
plant toxin ricin. The targets for these kinases are still not known.
However, it has been found that Shiga toxin induces formation of a
complex between p38 and arrestin [67], and there is a toxin-in-
duced increase in endosomal association of both p38 and arrestin
[67]. Interestingly, the increase in endosomal localization of arres-
tin is inhibited upon knockdown of p38, and together these results
suggest that arrestin may modulate the effect of p38. Indeed, we
found that downregulation of arrestin increased Golgi transport
of Shiga toxin [67], but again, we do not have a complete under-
standing of the mechanisms involved.
4.3. Modulation of membrane lipids and effect on transport
to the Golgi apparatus
Lipid rafts, membrane areas rich in cholesterol and glyco-
sphingolipids with long, saturated fatty acids, are found both in
the plasma membrane, in endosomal structures, and in the Golgi
apparatus [69]. Rafts may serve as signaling platforms and are a
prerequisite for structures such as caveolae [70,71]. However, cho-
lesterol is also essential to obtain a certain thickness of the mem-
brane and to ensure low permeability to ions, and membrane
cholesterol can be essential to anchor molecules such as annexins
to the membrane [72]. A common way to reduce membrane cho-
lesterol in order to study its role for a certain process is to add
methyl-b-cyclodextrin which extracts cholesterol from the mem-
brane. Several years ago we found that addition of cyclodextrin re-
duces transport of ricin from endosomes to the Golgi apparatus
[73], and similarly, this was found to be the case also for Shiga tox-
in transport to the Golgi apparatus [74]. These results lead to the
suggestion that lipid rafts might be important for toxin transport
from endosomes to the Golgi apparatus. However, although it
might be the case for a toxin such as Shiga toxin that binds to a gly-
cosphingolipid, this does not seem to be the case for toxins in gen-
eral. It is important to note that in the case of ricin, toxin transport
to the Golgi (measured as sulfation of a genetically modiﬁed toxin
molecule) and retrograde transport to the cytosol (measured as
intoxication), occurs equally well in cells unable to synthesize
glycosphingolipids [28]. In these studies, a mouse melanoma cell
line lacking glucosylceramide transferase (GM95 cells) as well as
a back-transfectant (GM95-CGlcT-KKVK) were used. However,
these cells do contain normal amounts of sphingomyelin, and since
cholesterol depletion could inhibit Golgi transport also in glyco-
sphingolipid-deﬁcient cells, one might argue that ricin bound to
glycoprotein receptors found in lipid rafts were important for Golgi
transport and retrograde transport. To investigate lipid require-
ments in more detail, also cells with a general defect in sphingo-
lipid synthesis were investigated. A CHO-cell line (LY-B cells)
lacking serine palmitoyl transferase and the mutant with back-
transfection of the enzyme, as well as the mother cell line were
studied [26]. When the cells without serine palmitoyl transferase
are incubated without serum for 2 days the sphingolipid level is re-
duced more than 70%. Interestingly, Golgi transport of ricin was in-
creased in cells with reduced levels of sphingolipids suggesting
that rafts might even restrict transport of ricin to the Golgi appara-
tus. Further retrograde transport of ricin to the endoplasmic retic-
ulum (ER) and the cytosol, measured as toxicity, was also
increased. Interestingly, cholesterol depletion could still reduce
the transport between endosomes and the Golgi apparatus in cells
depleted for sphingolipids, suggesting that cholesterol depletion
might affect association of endosomes with cytoskeletal elements
or other proteins of importance for transport or fusion. Additionof sphinganine to the cells unable to synthesize this intermediate
reversed the effect on ricin transport. Moreover, an inhibitor of ser-
ine palmitoyl transferase, myriosin, sensitized cells to ricin. Of
interest in this connection is the ﬁnding that most of the ricin that
was transported to the Golgi apparatus (sulfated ricin) was not
associated with detergent-resistant membranes. Thus, in the case
of ricin transport, there is no evidence for a requirement for lipid
rafts for retrograde transport. Actually, also other protein toxins,
such as abrin, modeccin and Pseudomanas exotoxin A had a larger
toxic effect on LY-B cells lacking sphingolipids than on the back-
transfectant with normal sphingolipids [26] suggesting that also
their retrograde transport actually works better at low levels of
sphingolipids.
In the case of Shiga toxin the type of fatty acids present in Gb3
may be important not only for cell surface binding and endocyto-
sis, but also for Golgi transport [3,6,27]. The ﬁrst observation of ret-
rograde transport of Shiga toxin was made after incubation of A431
cells with butyric acid which changes the glycosphingolipid con-
tent in cells, and which in A431 cells allowed us to visualize Shiga
toxin not only in the Golgi apparatus but also in the ER and the nu-
clear envelope [75,76]. Different types of experiments indicated
that the changed transport was associated with a change in lipid
composition. This was the ﬁrst time that a cell surface-bound mol-
ecule was found to be transported all the way from the cell surface
to endosomes, the Golgi, the ER and the nuclear envelope. Since
then, similar transport has been demonstrated also for other tox-
ins, such as cholera toxin and ricin, and for native cellular proteins
[3,4,77,78].
We recently found that when synthesis of new glyco-
sphingolipids was inhibited for a short time by PDMP or by fumon-
isin B1 in HEp-2 cells, there was a slight inhibition of endocytosed
toxin (less than 40%) under conditions when Golgi transport was
reduced more than 10 times [27]. During the incubation with
inhibitors there was a selective disappearance of glyco-
sphingolipids with certain fatty acids, the fastest reduction (prob-
ably due to sorting to lysosomes and degradation) was found for
(glyco)-sphingolipids with the N-amidated fatty acid 16:0. How-
ever, whether this fatty acid somehow facilitates endosome-to-
Golgi transport still needs to be investigated. Interestingly, under
conditions where reduced Shiga toxin transport to the Golgi was
seen, there was also a redistribution of SNX1 and SNX2, away from
the Golgi apparatus. Since SNX1 and SNX2 are involved in Shiga
transport to the Golgi, these ﬁndings are likely to be related to
the observed change in toxin transport. Perhaps the lipid changes
somehow alter the curvature of membranes and association with
molecules containing BAR-domains [61]. Interestingly, PDMP and
fumonisin B1 had no effect on ricin transport. Although ricin trans-
port to the Golgi has been found to be partly SNX2-dependent [60]
it is also SNX4-dependent [67], and reduction of ricin transport by
one pathway may allow the toxin to be transported by another
route. The effects obtained upon addition of inhibitors of glyco-
sphingolipid synthesis could be cell line dependent as it was re-
ported that in the HeLa cells studied by Smith et al. [79] such
inhibitors lead to inhibition of Shiga transport at a stage after arri-
val to the Golgi apparatus.
Cell type dependent differences in intracellular transport should
be expected, as the cellular lipid compositions vary. The overview
of cell lines in Table 1 reveals large differences in the Gb3 species.
One should be careful in interpreting small differences between
these numbers, as different analytical methods were used. A quan-
titative standard for MS analysis of Gb3 species has not been avail-
able until very recently, and MS data have been restricted to
estimating the ratio between different Gb3 species, but not to
determine the exact concentration of these species. The remark-
able large differences reported for HeLa cells in two different stud-
ies (Table 1) should be noted [79,80]. One may wonder if these
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ingly, similar data for Gb3 species in the plasma membranes and
internal membranes of HeLa cells were reported [80], whereas
the detergent-resistant fraction showed a 7% higher content of
fatty acid 16:0 and a 10% lower content of fatty acid 24:1. There
are several indications in the literature that Gb3 species with N-
amidated fatty acid 16:0 is important for the toxicity of Shiga tox-
in. Arab and Lingwood [81] analyzed the Gb3 composition of two
astrocytoma cell lines (XF-498 and the multi drug resistant SF-
539) and two ovarian cell lines (SKOV3 and its multi drug resistant
variant SKVLB). When comparing the drug resistant and drug sen-
sitive cell line pairs, it was found that the drug resistant cell type
was at least 1000 times more sensitive to Shiga toxin than the drug
sensitive counterpart. The data in Table 1 show that the most sen-
sitive astrocytoma cell line (SF-539) and the most sensitive ovarian
cell line (SKVLB) both contained a higher fraction of the 16:0 fatty
acid than the less sensitive corresponding cell lines (i.e. the astro-
cytoma cell line XF-498 and the ovarian cell line SKOV3). It was re-
ported that SF-539 expressed slightly lower levels of Gb3 than XF-
498 as analyzed with HPLC [81], whereas binding of Shiga toxin to
thin layer chromatograms showed more binding to SF-539 than to
XF-498 cells [82]. As discussed elsewhere, toxin binding does not
necessarily correlate with the Gb3 level. Remarkably, the most sen-
sitive ovarian cell (SKVLB) was reported to contain very low
amounts of N-amidated fatty acids with 20 carbons or more (ap-
prox. 5% of total Gb3). HBMEC (human brain microvascular endo-
thelial cells) and EA.hy 926 (a cell line derived by fusing human
umbilical vein endothelial cells (HUVECs) to the lung epithelial cell
line A549) seem to contain rather similar composition of Gb3 spe-
cies (Table 1). For these cell lines, the much higher total amount of
Gb3 species (as revealed by orcinol staining of thin layer chromato-
grams) in the EA.hy 926 cells compared to the HBMEC cells may
explain the 1000x higher sensitivity of the EA.hy 926 cells to Shiga
toxin [83,84].
In agreement with the idea that the types of fatty acids present
in the membrane lipids are important for Shiga toxin transport,
incubation of cells with poly-unsaturated fatty acids (PUFAs) such
as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for
2 days was found to protect against Shiga toxin [85]. The protec-
tion was mainly due to reduced endosome-to-Golgi transport,
but also endocytosis of the toxin was inhibited. In contrast to the
protective effect of PUFAs against Shiga toxin, there was a sensiti-
zation to ricin and Pseudomonas exotoxin A. Clearly, not only pro-
teins involved in transport to the Golgi vary for the different toxins,
also various types of lipids have a differential effect on toxin
transport.Fig. 3. Intracellular localization of ricinB:QD705 bioconjugates in HeLa cells. The
QD bioconjugates were internalized by the cells for 3 hours at 37 C. The cells were
then ﬁxed and prepared for immunoﬂuorescence microscopy imaging by labeling
them with antibodies against the lysosomal marker CD63, followed by the
corresponding secondary antibody-Cy2 conjugate. The image shows the QD
bioconjugates in red and CD63 stained with the Cy2 ﬂuorophore in green. Yellow
color indicates colocalization. The ricinB:QDs display partial colocalization (30%)
with CD63 after 3 h of internalization.5. Retrograde transport of Shiga toxin and ricin to the ER
and the cytosol
Transport pathways of cellular proteins and lipids through the
Golgi apparatus have been debated for decades, and even today,
it is not clear to which extent different molecules are transferred
by vesicles, by maturation of cisterns, or by tubular connections
[86]. One of the best studied ways to bring molecules from the
Golgi to the ER is via COPI-coated vesicles after binding to the
KDEL-receptor. However, neither Shiga toxin nor ricin have such
a sequence (KDEL), and Shiga toxin transport has been found to
be COPI-independent, but dependent on actin and microtubules,
Cdc42 and Yip1A [87–91–93]. Also, ricin transport to the ER seems
to occur independently of COPI-coated vesicles [94]. This is in con-
trast to the toxin Pseudomonas exotoxin A which seems to depend
on empty KDEL-receptors for its retrograde transport [95]. If these
receptors are saturated by overexpression of the protein lysozyme-
KDEL, toxicity of Pseudomonas exotoxin A is abolished. Also, whenthe KDEL-receptor is redistributed out of the Golgi by activation of
Src, cells are protected against Pseudomonas exotoxin A [96]. These
ﬁndings illustrate the ability of the toxins to exploit different
mechanisms. Importantly, it was recently shown that molecules
that bind the KDEL-receptors can induce signaling which again
can affect transport through the Golgi apparatus [97]. Some of
the toxins might therefore affect also the transport through the
Golgi apparatus. Clearly, constructs such as the Shiga B-subunit
with a KDEL-sequence are not likely to follow the route normally
used by Shiga toxin. A KDEL-containing molecule is most likely
transported by the COPI-mechanism, and in addition it might
change transport through signaling.
Translocation of toxins from the ER and into the cytosol can oc-
cur after reduction of the internal disulﬁde bond connecting the
enzymatically active part of the toxin with the rest of the molecule,
and several ER chaperones and components have been described to
be of importance for translocation to the cytosol. For instance,
HEDJ/ERdj3 and BIP [98] were found to be important for Shiga tox-
in transport, and EDEM seems to be involved in ricin transport [99].
Although both ricin [78] and Shiga toxin [98] were reported to
form a complex with Sec61p, its role in translocation is not yet
clariﬁed.6. Uptake of nanoparticles in cells: effect on transport of toxins
Protein toxins or rather their binding subunits can be used to di-
rect nanoparticles to cells and to mediate their endocytosis. In a re-
cent study we found that the ricinB:quantum dots (QDs) were
effectively endocytosed, whereas the Shiga:QDs were internalized
more slowly than Shiga toxin. Neither the Shiga:QDs nor the ri-
cin:QDs were routed to the Golgi apparatus as would be the case
for Shiga toxin and ricin, but they accumulated within late endo-
somes. Fig. 3 shows the intracellular localization of ricinB:QD bio-
conjugates in HeLa cells. Moreover, the toxins can also be used to
test whether the internalization of nanoparticles affect normal
transport. Remarkably, it turns out that internalization of quantum
dots (QDs) may increase Golgi transport of Shiga toxin whereas it
2632 K. Sandvig et al. / FEBS Letters 584 (2010) 2626–2634reduces retrograde ricin transport [100]. Thus, such studies of toxin
transport can be useful to examine the consequences of particle
internalization. In fact, this type of information is highly needed
before intravenously injected nanoparticles can be commonly used
in medicine. Future studies are required to learn if particles actu-
ally can be used to follow toxins on their retrograde journey.
7. Use of protein toxins in medicine
It is a very old idea that toxins can be directed to for instance can-
cer cells [18,101], either by coupling them to antibodies or by using
ligands such as interleukins to direct the toxins to certain cell types
[14,16,30,102]. In spite of many trials, the only approved product so
far is a diphtheria toxin conjugate where interleukin 2 serves as the
binding moiety [103–105]. However, as methodology is improving
and more becomes known about entry mechanisms and the role of
different parts of the toxin molecules, new improved drugs can be
produced, and clinical trials are ongoing. The toxins may be used
to bring in epitopes that produce an immune response leading to
protection against cancer cells, and the binding part of Shiga toxin
has been used to transport a prodrug against colon cancer to the
ER where it is released by the reducing conditions and then
transported to the cytosol [3]. Moreover, the toxin B-subunit can,
following conjugation to porphyrins, also potentiate the toxic effect
of these chemicals (for review, see [3]). Furthermore, the toxin can
be used as a vector to bring DNA into cells [106]. Interestingly, the
Shiga toxin receptor, Gb3, is to a certain extent overexpressed on
cancer cells (compared to normal cells) [15,107,108], and (Engedal,
N., Skotland, T., Torgersen, M.L. and Sandvig, K., submitted), and in
the case of colon cancer cells it seems to be associatedwith the abil-
ity tometastasize [108]. This has raised the idea of using Shiga toxin
(or its B subunit) for diagnosis of cancer cells, and the principle has
been shown to work in murine models [3]. Thus, the future use of
protein toxins in diagnosis and therapy might prove to be a useful
aspect of these interesting molecules.
8. Conclusion
As discussed in the current review, studies of protein toxins are
useful for several purposes. The toxins are still a problem in con-
nection with infectious diseases, and they may be a threat as bio-
terror weapons. However, they serve as excellent tools to study
cellular mechanisms, and increased knowledge about the toxins
may give us new products for use in medicine, both when it comes
to diagnosis and therapy of diseases such as cancer.
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